Suboxone (film formulation)

GPTKB entity

Statements (52)
Predicate Object
gptkbp:instanceOf gptkb:drug
gptkbp:activeIngredient gptkb:naloxone
gptkb:buprenorphine
gptkbp:approvalYear 2010
gptkbp:ATCCode N07BC51
gptkbp:brand buprenorphine/naloxone
gptkbp:contraindication hypersensitivity to naloxone
hypersensitivity to buprenorphine
gptkbp:firstApprovedCountry gptkb:United_States
gptkbp:form gptkb:film
12 mg/3 mg
2 mg/0.5 mg
4 mg/1 mg
8 mg/2 mg
gptkbp:genericAvailable yes
https://www.w3.org/2000/01/rdf-schema#label Suboxone (film formulation)
gptkbp:indication opioid dependence
gptkbp:isSolubleIn mouth
gptkbp:legalStatus gptkb:Schedule_III
gptkbp:manufacturer Indivior
gptkbp:pregnancyCategory C
gptkbp:prescriptionStatusUS prescription only
gptkbp:riskFactor gptkb:orthostatic_hypotension
gptkb:serotonin_syndrome
dizziness
fatigue
hepatitis
allergic reaction
QT prolongation
drowsiness
respiratory depression
liver toxicity
drug interactions
dependence
adrenal insufficiency
abuse potential
mouth irritation
neonatal opioid withdrawal syndrome
precipitated withdrawal
mouth numbness
mouth redness
gptkbp:routeOfAdministration sublingual
buccal
gptkbp:sideEffect nausea
constipation
headache
sweating
insomnia
gptkbp:storage 20-25°C (68-77°F)
gptkbp:usedFor medication-assisted treatment
gptkbp:bfsParent gptkb:Aquestive_Therapeutics
gptkbp:bfsLayer 7